These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 22851273)

  • 1. Early detection tools for pancreatic cancer.
    Schmidt C
    J Natl Cancer Inst; 2012 Aug; 104(15):1117-8. PubMed ID: 22851273
    [No Abstract]   [Full Text] [Related]  

  • 2. K-ras mutations in the plasma correspond to computed tomographic findings in patients with pancreatic cancer.
    Däbritz J; Preston R; Hänfler J; Oettle H
    Pancreas; 2012 Mar; 41(2):323-5. PubMed ID: 22044911
    [No Abstract]   [Full Text] [Related]  

  • 3. Genetic alterations of K-ras, p53, c-erbB-2, and DPC4 in pancreatic ductal adenocarcinoma and their correlation with patient survival.
    Shin SH; Kim SC; Hong SM; Kim YH; Song KB; Park KM; Lee YJ
    Pancreas; 2013 Mar; 42(2):216-22. PubMed ID: 23344532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. K-ras mutations in circulating DNA from pancreatic and lung cancers: bridging methodology for a common validation of the molecular diagnosis value.
    Magistrelli P; Neri M; Granone P; Cesario A; Paleari L; Russo P
    Pancreas; 2008 Jul; 37(1):101-2. PubMed ID: 18580451
    [No Abstract]   [Full Text] [Related]  

  • 5. Fluorescence in situ hybridization and K-ras analyses improve diagnostic yield of endoscopic ultrasound-guided fine-needle aspiration of solid pancreatic masses.
    Reicher S; Boyar FZ; Albitar M; Sulcova V; Agersborg S; Nga V; Zhou Y; Li G; Venegas R; French SW; Chung DS; Stabile BE; Eysselein VE; Anguiano A
    Pancreas; 2011 Oct; 40(7):1057-62. PubMed ID: 21705950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. KRAS mutations in codon 12 or 13 are associated with worse prognosis in pancreatic ductal adenocarcinoma.
    Sinn BV; Striefler JK; Rudl MA; Lehmann A; Bahra M; Denkert C; Sinn M; Stieler J; Klauschen F; Budczies J; Weichert W; Stenzinger A; Kamphues C; Dietel M; Riess H
    Pancreas; 2014 May; 43(4):578-83. PubMed ID: 24681874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular biomarkers for progression of intraductal papillary mucinous neoplasm of the pancreas.
    Kuboki Y; Shimizu K; Hatori T; Yamamoto M; Shibata N; Shiratori K; Furukawa T
    Pancreas; 2015 Mar; 44(2):227-35. PubMed ID: 25423558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Translational research in pancreatic cancer: KRAS and beyond.
    Boeck S; Ormanns S; Haas M; Bächmann S; Laubender RP; Siveke JT; Jung A; Kirchner T; Heinemann V
    Pancreas; 2014 Jan; 43(1):150-2. PubMed ID: 24326376
    [No Abstract]   [Full Text] [Related]  

  • 9. An improved quantitative mass spectrometry analysis of tumor specific mutant proteins at high sensitivity.
    Ruppen-Cañás I; López-Casas PP; García F; Ximénez-Embún P; Muñoz M; Morelli MP; Real FX; Serna A; Hidalgo M; Ashman K
    Proteomics; 2012 May; 12(9):1319-27. PubMed ID: 22589181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autophagy, p53, and pancreatic cancer.
    Iacobuzio-Donahue CA; Herman JM
    N Engl J Med; 2014 Apr; 370(14):1352-3. PubMed ID: 24693896
    [No Abstract]   [Full Text] [Related]  

  • 11. Next-generation strategies for hereditary colorectal cancer risk assessment.
    Yurgelun MB
    J Clin Oncol; 2015 Feb; 33(5):388-93. PubMed ID: 25559814
    [No Abstract]   [Full Text] [Related]  

  • 12. Pancreatic cancer research matures.
    Nelson NJ
    J Natl Cancer Inst; 2007 Oct; 99(19):1432-4. PubMed ID: 17895469
    [No Abstract]   [Full Text] [Related]  

  • 13. The discrete nature and distinguishing molecular features of pancreatic intraductal tubulopapillary neoplasms and intraductal papillary mucinous neoplasms of the gastric type, pyloric gland variant.
    Yamaguchi H; Kuboki Y; Hatori T; Yamamoto M; Shimizu K; Shiratori K; Shibata N; Shimizu M; Furukawa T
    J Pathol; 2013 Nov; 231(3):335-41. PubMed ID: 23893889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Significance of Combined Measurement of p53 Antibody and other Tumor Markers for Colorectal Cancer after Curative Resection.
    Kawahara D; Fujita F; Hayashi H; Matsuyama T; Eguchi S
    Hepatogastroenterology; 2015 May; 62(139):624-8. PubMed ID: 26897942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Challenges and opportunities for use of cost-effectiveness analysis.
    Yabroff KR; Schrag D
    J Natl Cancer Inst; 2009 Sep; 101(17):1161-3. PubMed ID: 19666852
    [No Abstract]   [Full Text] [Related]  

  • 16. Individualized adjuvant chemotherapy for surgically resected lung cancer and the roles of biomarkers.
    Ikeda N; Nagase S; Ohira T
    Ann Thorac Cardiovasc Surg; 2009 Jun; 15(3):144-9. PubMed ID: 19597387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of KRAS gene mutations in endoscopic ultrasound-guided fine-needle aspiration biopsy for improving pancreatic cancer diagnosis.
    Wang X; Gao J; Ren Y; Gu J; Du Y; Chen J; Jin Z; Zhan X; Li Z; Huang H; Lv S; Gong Y
    Am J Gastroenterol; 2011 Dec; 106(12):2104-11. PubMed ID: 21876563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pancreatic cancer: new hopes for early detection and a future screening tool?
    El-Jurdi NH; Saif MW
    JOP; 2014 Jul; 15(4):358-9. PubMed ID: 25076343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low value of detection of KRAS2 mutations in circulating DNA to differentiate chronic pancreatitis to pancreatic cancer.
    Marchese R; Muleti A; Brozzetti S; Gandini O; Brunetti E; French D
    Br J Cancer; 2004 Jun; 90(11):2243. PubMed ID: 15150585
    [No Abstract]   [Full Text] [Related]  

  • 20. Diagnostic accuracy of K-ras mutation for pancreatic carcinoma: a meta-analysis.
    Liu SL; Chen G; Zhao YP; Wu WM; Zhang TP
    Hepatobiliary Pancreat Dis Int; 2013 Oct; 12(5):458-64. PubMed ID: 24103274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.